TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference
Rhea-AI Summary
TuHURA Biosciences (NASDAQ:HURA) announced that President and CEO James A. Bianco, M.D., will present at Canaccord Genuity's 46th Annual Growth Conference in Boston, MA, on Wednesday, August 12, 2026 at 12:30 p.m. ET. A live registration link and an archived webcast will be available via the Investor Section of TuHURA's website, alongside an “Ask Me Anything” interview with Dr. Bianco.
Positive
- None.
Negative
- None.
News Market Reaction – HURA
In the Jul 22 session, HURA gained 1.36%, reflecting a mild positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 15 | IND filing | Neutral | -2.2% | FDA submission for TBS-2025 in AML and other blood cancers |
| May 15 | First-quarter earnings | Positive | +10.4% | Credit facility, royalty transaction, and corporate update extended anticipated runway |
| May 12 | Investor conference | Neutral | +0.8% | CEO scheduled to participate in an H.C. Wainwright investor conference |
| Apr 22 | Credit facility | Positive | +4.1% | Company secured financing and royalty transaction supporting anticipated cash runway |
| Apr 07 | Leadership appointment | Positive | +1.7% | Amanda Garofalo appointed senior vice president of clinical operations |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Historical reactions included gains after positive corporate updates, a decline after the IND filing, and a 0.83% increase after a prior investor-conference announcement.
Key Terms
phase 3 medical
immuno-oncology medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Canaccord Genuity 46th Annual Growth Conference
Date: | Wednesday, August 12, 2026 |
Time: | 12:30pm ET |
To register and view the presentation, please CLICK HERE.
An archived webcast of the Canaccord presentation will be available on the Events Page in the Investor Section of TuHURA's website. Additionally, investors and stakeholders are encouraged to view the "Ask Me Anything" interview of Dr. Bianco available HERE.
About TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer.
TuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is enrolling patients in its randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) compared to Keytruda® plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
In addition to its innate immune agonist product candidates, TuHURA is developing TBS-2025, a VISTA inhibiting mAb moving into dose escalation/optimization Phase 1b trial in mutNPM1 r/r AML, a molecularly defined subgroup representing approximately
For more information, please visit www.tuhurabio.com and connect with TuHURA on Facebook, X, and LinkedIn.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain "forward-looking statements" within the meaning of, and subject to the safe harbor created by, Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These Forward-Looking Statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases, you can identify these statements by forward-looking words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "should," "would," "project," "plan," "expect," "goal," "seek," "future," "likely," or the negative or plural of these words or similar expressions. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include, among others: the risks relating to the timing and nature of the FDA's response to the Company's re-filed IND for TBS-2025; the risks associated with the timing and results of conducting the planned Phase 1b/2 trial of TBS-2025, including the risks related to patient enrollment, trial design, data outcomes and regulatory interactions; uncertainty regarding the timing and likelihood of regulatory approvals; and the other risks described from time to time in detail in Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed on March 31, 2026, and TuHURA's other reports and filings with the SEC from time to time, which are available on TuHURA's website and at www.sec.gov. The forward-looking statements and other information contained in this press release are made as of the date hereof, and TuHURA does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Investor Contact:
Monique Kosse
Gilmartin Group
Monique@GilmartinIR.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/tuhura-biosciences-to-present-at-canaccord-genuitys-46th-annual-growth-conference-302831522.html
SOURCE TuHURA Biosciences, Inc.